Subtopic Deep Dive
Radioimmunotherapy Agents
Research Guide
What is Radioimmunotherapy Agents?
Radioimmunotherapy agents are monoclonal antibody conjugates labeled with beta- or alpha-emitting radionuclides for targeted treatment of hematologic and solid tumors expressing specific antigens.
These agents deliver radiation directly to cancer cells via antigen-specific binding, minimizing damage to healthy tissue. Key examples include 90Y-ibritumomab tiuxetan (Zevalin) for non-Hodgkin's lymphoma (Wiseman et al., 2000, 233 citations) and folate receptor-targeted conjugates with terbium or lutetium isotopes (Müller et al., 2012, 243 citations; Müller et al., 2012, 177 citations). Over 10 papers from the provided list address linker chemistry, dosimetry, and theragnostic pairs like 44Sc/47Sc (Müller et al., 2014, 209 citations).
Why It Matters
Radioimmunotherapy agents enable precise tumor irradiation, improving survival in relapsed non-Hodgkin's lymphoma as shown in phase I/II trials with 90Y-Zevalin (Wiseman et al., 2000). Folate receptor-targeted constructs with albumin-binding DOTA conjugates allow 177Lu therapy in mice by enhancing tumor-to-kidney ratios (Müller et al., 2012). Terbium quadruplets support matched PET/SPECT imaging and α/β- therapy for folate receptor-positive tumors (Müller et al., 2012), while reviews highlight clinical advances and challenges in cancer therapy (Sgouros et al., 2020).
Key Research Challenges
Linker Stability In Vivo
Chelators like DOTA must withstand serum conditions to prevent radionuclide dissociation. Elevated temperature and optimized pH improve DOTA-protein conjugation stability (Lewis et al., 1994, 163 citations). Instability leads to off-target toxicity (Sgouros et al., 2020).
Immunogenicity of Conjugates
Antibody-radiometal complexes can trigger immune responses reducing efficacy. Early immunoconjugates faced immunogenicity barriers in solid tumor targeting (Sharkey et al., 2006, 243 citations). Humanized antibodies mitigate this but require optimization (Sgouros et al., 2020).
Dosimetry and Toxicity Management
Accurate dosimetry is critical for beta-emitters like 90Y-Zevalin in lymphoma (Wiseman et al., 2000, 233 citations). Kidney protection strategies, such as albumin-binding, are needed for folate-targeted 177Lu (Müller et al., 2012, 177 citations). Balancing efficacy and myelosuppression remains challenging (Sgouros et al., 2020).
Essential Papers
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros, Lisa Bodei, Michael R. McDevitt et al. · 2020 · Nature Reviews Drug Discovery · 831 citations
Advances in targeting the folate receptor in the treatment/imaging of cancers
Marcos Fernández, Faiza Javaid, Vijay Chudasama · 2017 · Chemical Science · 534 citations
The folate receptor (FR) is an important biomarker for many cancers, and its overexpression on tumours can be exploited for targeted therapy, diagnosis and imaging.
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Robert M. Sharkey, David M. Goldenberg · 2006 · CA A Cancer Journal for Clinicians · 243 citations
Immunotherapy of cancer has been explored for over a century, but it is only in the last decade that various antibody-based products have been introduced into the management of patients with divers...
A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β<sup>−</sup>-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative
Cristina Müller, Konstantin Zhernosekov, U. Köster et al. · 2012 · Journal of Nuclear Medicine · 243 citations
For the first time, to our knowledge, 4 terbium radionuclides have been tested in parallel with tumor-bearing mice using an FR targeting agent. Along with excellent tumor visualization enabled by (...
Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
Gregory A. Wiseman, Christine A. White, Michael Stabin et al. · 2000 · European Journal of Nuclear Medicine and Molecular Imaging · 233 citations
Promising Prospects for <sup>44</sup>Sc-/<sup>47</sup>Sc-Based Theragnostics: Application of <sup>47</sup>Sc for Radionuclide Tumor Therapy in Mice
Cristina Müller, Maruta Bunka, Stephanie Haller et al. · 2014 · Journal of Nuclear Medicine · 209 citations
With this study, we demonstrated the suitability of using (47)Sc for therapeutic purposes. On the basis of our recent results obtained with (44)Sc-folate, the present work confirms the applicabilit...
<sup>68</sup>Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer
Wolfgang P. Fendler, Dorothea Schmidt, Vera Wenter et al. · 2016 · Journal of Nuclear Medicine · 201 citations
<sup>68</sup>Ga-PSMA PET/CT accurately detected the location and extent of primary prostate cancer. Our preliminary findings warrant further investigation of <sup>68</sup>Ga-PSMA PET/CT in conjunct...
Reading Guide
Foundational Papers
Start with Sharkey et al. (2006, 243 citations) for antibody immunoconjugate history; Wiseman et al. (2000, 233 citations) for 90Y-Zevalin clinical dosimetry; Lewis et al. (1994, 163 citations) for DOTA conjugation methods.
Recent Advances
Sgouros et al. (2020, 831 citations) for therapy challenges; Eychenne et al. (2021, 173 citations) for alpha-emitters; Müller et al. (2014, 209 citations) for Sc-theragnostics.
Core Methods
DOTA-sulfo-NHS activation (Lewis et al., 1994); albumin-binding folate conjugates (Müller et al., 2012); terbium/Sc matched pairs for PET/SPECT/therapy (Müller et al., 2012; Müller et al., 2014).
How PapersFlow Helps You Research Radioimmunotherapy Agents
Discover & Search
Research Agent uses searchPapers and citationGraph to map 250M+ papers, revealing Sgouros et al. (2020, 831 citations) as the top-cited review on radioimmunotherapy challenges, then findSimilarPapers uncovers Müller et al. (2012) terbium studies for theragnostics.
Analyze & Verify
Analysis Agent applies readPaperContent to extract dosimetry data from Wiseman et al. (2000), verifies claims with CoVe against OpenAlex metadata, and runs PythonAnalysis with pandas to compare half-lives of 47Sc vs 177Lu from Müller et al. (2014), graded by GRADE for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in alpha-emitter immunogenicity via contradiction flagging across Sharkey (2006) and Eychenne (2021), while Writing Agent uses latexEditText, latexSyncCitations for 90Y-Zevalin sections, and latexCompile to generate a review manuscript with exportMermaid diagrams of chelator structures.
Use Cases
"Analyze survival data and dosimetry from 90Y-Zevalin phase trials"
Research Agent → searchPapers('Wiseman 2000 Zevalin') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas survival curves, matplotlib plots) → researcher gets verified Kaplan-Meier plots and statistical p-values.
"Draft LaTeX review on terbium radioimmunotherapy for folate tumors"
Synthesis Agent → gap detection (Müller 2012 papers) → Writing Agent → latexGenerateFigure (Tb quadruplet decay schemes) + latexSyncCitations + latexCompile → researcher gets compiled PDF with diagrams and 20+ citations.
"Find code for DOTA conjugation simulations in radioimmunotherapy"
Research Agent → paperExtractUrls (Lewis 1994) → Code Discovery → paperFindGithubRepo + githubRepoInspect → researcher gets Python scripts for chelate stability modeling with NumPy simulations.
Automated Workflows
Deep Research workflow systematically reviews 50+ papers on beta-emitters: searchPapers('radioimmunotherapy agents') → citationGraph → DeepScan 7-step analysis with CoVe checkpoints on Sgouros (2020). Theorizer generates hypotheses on 225Ac-alpha therapy combinations from Eychenne (2021), chaining gap detection to exportMermaid nuclide decay networks.
Frequently Asked Questions
What defines radioimmunotherapy agents?
Monoclonal antibody conjugates with beta- or alpha-emitters target tumor antigens, as in 90Y-ibritumomab tiuxetan for lymphoma (Wiseman et al., 2000).
What are key methods in radioimmunotherapy?
DOTA chelation at optimized pH for protein labeling (Lewis et al., 1994); albumin-binding for kidney protection in 177Lu-folate (Müller et al., 2012); matched theragnostic pairs like 44Sc/47Sc (Müller et al., 2014).
What are landmark papers?
Sgouros et al. (2020, 831 citations) reviews clinical advances; Wiseman et al. (2000, 233 citations) reports Zevalin dosimetry; Müller et al. (2012, 243 citations) demonstrates terbium quadruplets.
What open problems exist?
Improving linker stability, reducing immunogenicity, and optimizing dosimetry for solid tumors (Sgouros et al., 2020); expanding alpha-emitters beyond 'hopeful eight' (Eychenne et al., 2021).
Research Radiopharmaceutical Chemistry and Applications with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Radioimmunotherapy Agents with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers